🇺🇸 FDA
Patent

US 10273291

Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing

granted A61KA61K39/42A61P

Quick answer

US patent 10273291 (Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing) held by THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH
Grant date
Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61K, A61K39/42, A61P, A61P31/18